Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

ML-004/

Other · developed by MapLight Therapeutics

Phase 2 Most advanced trial
MPLT Developer
1 Registered trials

What is ML-004/?

ML-004 is a drug studied in autism spectrum disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Psychiatry
Developer
MapLight Therapeutics (MPLT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05889273 Phase 2 Autism Spectrum Disorder Active not recruiting MPLT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Autism Spectrum Disorder

More from MapLight Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the MPLT page.

Follow MPLT, the company behind ML-004/

See MPLT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MPLT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.